New drug duo targets tough stomach cancers
NCT ID NCT05620628
Summary
This study is testing whether combining two drugs, savolitinib and durvalumab, can help control advanced stomach cancer that has a specific genetic feature (MET amplification) and has worsened after initial chemotherapy. The goal is to see if this combination can slow or stop the cancer's growth and is safe for patients. About 25 adults with this type of cancer who meet strict health criteria will participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH CANCER, ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.